Compare ANNX & CASS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | CASS |
|---|---|---|
| Founded | 2011 | 1906 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Business Services |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 726.1M | 714.9M |
| IPO Year | 2020 | 1996 |
| Metric | ANNX | CASS |
|---|---|---|
| Price | $4.03 | $54.44 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 2 |
| Target Price | $15.43 | ★ $59.50 |
| AVG Volume (30 Days) | ★ 3.0M | 58.1K |
| Earning Date | 11-09-2026 | 10-30-2026 |
| Dividend Yield | N/A | ★ 2.34% |
| EPS Growth | N/A | ★ 87.77 |
| EPS | N/A | ★ 1.48 |
| Revenue | N/A | ★ $190,750,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $6.52 |
| P/E Ratio | ★ N/A | $36.88 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.54 | $37.74 |
| 52 Week High | $7.18 | $59.63 |
| Indicator | ANNX | CASS |
|---|---|---|
| Relative Strength Index (RSI) | 44.50 | 55.36 |
| Support Level | $3.71 | $51.22 |
| Resistance Level | $4.37 | $59.63 |
| Average True Range (ATR) | 0.23 | 0.85 |
| MACD | -0.01 | 0.18 |
| Stochastic Oscillator | 49.27 | 89.44 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.
Cass Information Systems Inc is a provider of payment and information processing services to large manufacturing, distribution, and retail enterprises across the United States. The company provides transportation invoice rating, payment processing, auditing, accounting, and transportation information. It is also a processor and payer of energy invoices, including electricity, gas, waste, and other facility-related expenses. Additionally, the firm has a banking subsidiary, offering banking services mainly to privately held businesses in the St. Louis metropolitan area and restaurant franchises and faith-based ministries within the United States. The company operates in two reportable segments: Information Services, which generates the maximum revenue, and Banking Services.